Myocardial fibrosis in stroke survivors
Wong, K.; Sze, S.; Wong, S.; McSwiggan, S.; Allgar, V.; MacWalter, R.; Struthers, A. D.
A. D. Struthers
Stroke survivors are most likely to die of cardiac death, yet few undergo comprehensive cardiac assessment to look for reversible causes. Myocardial fibrosis (MF) is not only the hallmark of cardiomyopathy, but also a substrate for sudden cardiac death, ventricular tachyarrhythmia and heart failure. Procollagen carboxyl-terminal telopeptide (PICP) was found to be a marker of MF. The relationship between PICP and cardiac abnormalities in stroke survivors is unknown. We recently showed that MF in stroke survivors can be treated by spironolactone and amiloride in a randomised placebo-controlled cross-over study with reduction in PICP levels and QTc .
|Journal Article Type||Article|
|Publication Date||May 6, 2015|
|Journal||International journal of cardiology|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Wong, K., Sze, S., Wong, S., McSwiggan, S., Allgar, V., MacWalter, R., & Struthers, A. D. (2015). Myocardial fibrosis in stroke survivors. International journal of cardiology, 187(1), (138-140). doi:10.1016/j.ijcard.2015.03.212. ISSN 0167-5273|
|Keywords||Myocardial fibrosis, PICP, Stroke survivors|
|Copyright Statement||© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/|
|Additional Information||Author's accepted manuscript of article which has been published in International journal of cardiology, 2015, v.187.|
© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/